Korzenik JR - Search Results

1

Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab.

Korzenik JR. Korzenik JR. Gastroenterol Clin North Am. 2004 Jun;33(2):285-301, ix. doi: 10.1016/j.gtc.2004.02.009. Gastroenterol Clin North Am. 2004. PMID: 15177539 Review.

2

Infliximab maintenance therapy for fistulizing Crohn's disease.

Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Sands BE, et al. Among authors: korzenik jr. N Engl J Med. 2004 Feb 26;350(9):876-85. doi: 10.1056/NEJMoa030815. N Engl J Med. 2004. PMID: 14985485 Free article. Clinical Trial.

3

Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis.

Kaplan GG, Hur C, Korzenik J, Sands BE. Kaplan GG, et al. Aliment Pharmacol Ther. 2007 Dec;26(11-12):1509-20. doi: 10.1111/j.1365-2036.2007.03548.x. Epub 2007 Oct 11. Aliment Pharmacol Ther. 2007. PMID: 17931345

4

Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications.

Kunitake H, Hodin R, Shellito PC, Sands BE, Korzenik J, Bordeianou L. Kunitake H, et al. J Gastrointest Surg. 2008 Oct;12(10):1730-6; discussion 1736-7. doi: 10.1007/s11605-008-0630-8. Epub 2008 Aug 16. J Gastrointest Surg. 2008. PMID: 18709514

5

Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis.

Ananthakrishnan AN, Hur C, Juillerat P, Korzenik JR. Ananthakrishnan AN, et al. Among authors: korzenik jr. Am J Gastroenterol. 2011 Nov;106(11):2009-17. doi: 10.1038/ajg.2011.237. Epub 2011 Jul 26. Am J Gastroenterol. 2011. PMID: 21788991

6

Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn's disease: results of a decision analysis.

Ananthakrishnan AN, Hur C, Korzenik JR. Ananthakrishnan AN, et al. Among authors: korzenik jr. Dig Dis Sci. 2012 Feb;57(2):472-80. doi: 10.1007/s10620-011-1896-3. Epub 2011 Sep 11. Dig Dis Sci. 2012. PMID: 21909990

7

Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.

Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Cullen G, et al. Among authors: korzenik jr. Aliment Pharmacol Ther. 2011 Dec;34(11-12):1318-27. doi: 10.1111/j.1365-2036.2011.04866.x. Epub 2011 Sep 29. Aliment Pharmacol Ther. 2011. PMID: 21957906 Review.

8

Higher predicted vitamin D status is associated with reduced risk of Crohn's disease.

Ananthakrishnan AN, Khalili H, Higuchi LM, Bao Y, Korzenik JR, Giovannucci EL, Richter JM, Fuchs CS, Chan AT. Ananthakrishnan AN, et al. Among authors: korzenik jr. Gastroenterology. 2012 Mar;142(3):482-9. doi: 10.1053/j.gastro.2011.11.040. Epub 2011 Dec 9. Gastroenterology. 2012. PMID: 22155183 Free PMC article.

9

Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis.

Ananthakrishnan AN, Korzenik JR, Hur C. Ananthakrishnan AN, et al. Among authors: korzenik jr. Inflamm Bowel Dis. 2013 Jan;19(1):37-44. doi: 10.1002/ibd.22951. Inflamm Bowel Dis. 2013. PMID: 22416019

10

Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease.

Desai A, Zator ZA, de Silva P, Nguyen DD, Korzenik J, Yajnik V, Ananthakrishnan AN. Desai A, et al. Inflamm Bowel Dis. 2013 Feb;19(2):309-15. doi: 10.1002/ibd.23026. Inflamm Bowel Dis. 2013. PMID: 22605668 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

147 results

Search Page

Filters